# Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)

Study · id `cardio:ct-nct04088513` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04088513](<https://clinicaltrials.gov/study/NCT04088513>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04088513

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 440 participants.

## Technical summary

Registry record NCT04088513. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-22 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 440 participants (planned count; ClinicalTrials.gov record NCT04088513, source copy `cardio:ctgov-nct04088513-2022-03-16`, retrieved 2026-10-26)
- Started: 2020-01-22 (actual) (ClinicalTrials.gov record NCT04088513, source copy `cardio:ctgov-nct04088513-2022-03-16`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT04088513, source copy `cardio:ctgov-nct04088513-2022-03-16`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT04088513, source copy `cardio:ctgov-nct04088513-2022-03-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04088513, source copy `cardio:ctgov-nct04088513-2022-03-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04088513-2022-03-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
- Acronym: SAST
- Condition: G6PD Deficiency
- Condition: Stroke
- Intervention (Drug): Aspirin
- Intervention (Drug): Clopidogrel
- Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital, Sun Yat-Sen University (`cardio:org-first-affiliated-hospital-sun-yat-sen-university`)

## Provenance

Content hash: 22338a59ab990d434ba6ab44b32a545c54fb99079ce139bcb81bad7ccf74c239
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
